Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
- 1 June 2017
- journal article
- research article
- Published by Elsevier in Journal of Cardiology
- Vol. 69 (6) , 868-876
Abstract
No abstract availableKeywords
Funding Information
- American Heart Association
- National Center for Advancing Translational Sciences
- National Institutes of Health
- University of Minnesota Academic Health Center
This publication has 29 references indexed in Scilit:
- Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical PracticeCirculation: Cardiovascular Quality and Outcomes, 2016
- Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort studyThe Lancet Haematology, 2015
- Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial FibrillationCirculation, 2015
- Risk of Bleeding With Dabigatran in Atrial FibrillationJAMA Internal Medicine, 2015
- International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillationCurrent Medical Research and Opinion, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Rates and Implications for Hospitalization of Patients ≥65 Years of Age With Atrial Fibrillation/FlutterThe American Journal of Cardiology, 2012
- A systematic review of validated methods for identifying atrial fibrillation using administrative dataPharmacoepidemiology and Drug Safety, 2012
- Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007Circulation: Cardiovascular Quality and Outcomes, 2012
- Risk of Pelvic Fractures in Older Women Following Pelvic IrradiationJAMA, 2005